The pharmacokinetics of piroximone (PI) were determined in patients with renal failure (inulin clearance less than 50 ml min-' per 1.73 m2) using two protocols: (a) 10 patients received a single i.v. infusion of 0.5 mg kg-' PI and the data were compared with those from seven healthy subjects receiving the same regimen; (b), a single oral dose of either 25 or 50 mg PI was given to 20 patients. PI concentrations were assayed by h.p.l.c. in plasma and urine over 48 h. After i.v. administration to healthy subjects PI was distributed rapidly and eliminated with a mean half-life of 1.3 0.2 h. The urinary recovery of unchanged PI was 64% of the dose. In the patients the extent of renal elimination of PI was decreased (-78%) in relation to the degree of renal insufficiency as assessed by inulin clearance (r = 0.97, P < 0.0001). Mean Cmax, AUC and t'/2,1 values after i.v. infusion were increased by 47%, 127% and 77%, respectively, in comparison with healthy subjects. Similar results were obtained after oral administration. Until chronic dosing studies are undertaken, PI dosage should be adapted in relation to renal function.
Introduction Methods
Piroximone is a cardiotonic agent acting by specific inhibition of cAMP phosphodiesterase type III. Phosphodiesterase inhibitors may be an alternative to catecholamines in the treatment of advanced congestive heart failure because they are effective even when ,-receptors are down regulated. Piroximone (PI) improves left ventricular function by decreasing afterload and by a positive inotropic action [1, 2] . The pharmacokinetics of PI have been studied in healthy subjects as well as in patients with congestive heart failure at dosages ranging from 0.2 to 2 mg kg-' after i.v. and oral administration. Kinetics are linear with dose and are not influenced by cardiac failure. Oral bioavailability is greater than 80% [3, 4] . The terminal elimination half-life is short (1.7 ± 0.3 h) and urinary excretion of unchanged drug is the main route of elimination (68 ± 5% of an intravenously administered dose) [4] . We have studied the kinetics of PI in renal patients having a wide range of glomerular filtration rate after i.v. and oral administration.
PI pharmacokinetics were studied after either i.v. (first protocol) or oral administration (second protocol). Seven healthy volunteers (34 ± 6 years; creatinine clearance CLcr: 120 ± 18 ml min-1 per 1.73 m2) and ten patients with mild to severe renal insufficiency (50 ± 9 years; inulin clearance CLinul:
31 ± 15 ml min-' per 1.73 mi2) were included in the first protocol. Twenty patients with mild to severe renal insufficiency (52 ± 6 years, CLinul: 16 ml min-' per 1.73 mi2) were studied in the second protocol. None of the subjects had cardiac, pulmonary or liver disease. Patients did not receive any antibiotics or antiinflammatory drugs at least 8 days before the study. Blood pressure, heart rate, and electrocardiogram were monitored throughout the study. The study was approved by the local ethics committee and written consent was given by each individual.
Drug doses were administered after an overnight fast. For the first protocol, each subject received a 10-min i.v. infusion of a 0.5 mg kg-' dose of PI, 1.5 mg ml-' in 0.9% w/v sodium chloride. In the second study the patients were given 25 mg or 50 mg single oral PI doses. Venous heparinized blood samples were drawn and urine collected over 24 h. Samples of plasma and urine from the oral study were assayed for PI by solvent extraction followed by reversed phase h.p.l.c. This method allowed the measurement of PI up to 10 h after dosing. For were correlated with renal function, Cmax, r = 0.71, P < 0.01; MRT, r = 0.92, P < 0.001 and AUC, r = 0.90, P < 0.001 negatively; CL, r = 0.94, P < 0.001 positively and ti,2,,, r = 0.86, P < 0.01 reciprocally. Table 1 Pharmacokinetic parameters of piroximone in healthy volunteers (n = 7) and patients with renal impairment (n = 10) after intravenous administration and in patients with renal impairment after oral administration of 25 mg (n = 10) or 50 mg (n = 10) (from 7 to 49 ml min-1 per 1.73 mi2). A positive significant linear relation (r = 0.71, P < 0.0005) was found between renal clearance of PI and CL inul Subjective adverse events were noted in four patients (anxiety, n = 2; insomnia, n = 2; nausea, n = 1; headache, n = 1; thoracic constriction, n = 1) and were mild and brief.
Discussion
PI has a rapid elimination half-life and a clearance which is mostly renal under normal conditions. Extrarenal elimination becomes important only when renal function is impaired. In renal insufficient patients, PI was well tolerated. PI half-life increased in relation to renal impairment. However, the pharmacokinetic of PI appeared not to be linear. Until chronic dosing studies are undertaken, PI dosage should be adapted in relation to renal function.
